Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

681
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
681
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detailed analysis of the effects of a NOT gate on activation and growth of T cells.

Cytotherapy·2025
Same author

Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy.

Frontiers in immunology·2025
Same author

Editorial: The next stage of immune cell design: selective targeting of multi-antigen profiles.

Frontiers in immunology·2025
Same author

NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens.

iScience·2024
Same author

Geometric parameters that affect the behavior of logic-gated CAR T cells.

Frontiers in immunology·2024
Same author

Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity.

Cancer research communications·2023

Related Experiment Video

Updated: Sep 23, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

The Tmod cellular logic gate as a solution for tumor-selective immunotherapy.

Breanna DiAndreth1, Agnes E Hamburger1, Han Xu1

  • 1A2 Biotherapeutics, 30301 Agoura Rd., Agoura Hills, CA 91301, USA.

Clinical Immunology (Orlando, Fla.)
|May 13, 2022
PubMed
Summary

Engineered immune cells with NOT gates, like the Tmod system, offer selective cancer therapy. This approach targets solid tumors by integrating signals and selecting patients with specific genetic lesions for improved treatment outcomes.

Keywords:
CAR-TLILRB1LIR-1Logic gateNOT gateSynthetic biologyT cell therapy

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

728

Related Experiment Videos

Last Updated: Sep 23, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

728

Area of Science:

  • Immunology
  • Cancer Biology
  • Biotechnology

Background:

  • Engineered immune cells offer potential for targeted cancer therapies.
  • Achieving therapeutic selectivity remains a significant challenge in oncology.
  • Multi-signal integrators, such as NOT gates, are being explored to enhance treatment precision.

Purpose of the Study:

  • To review the Tmod system, a NOT-gated signal integrator for cancer immunotherapy.
  • To highlight the potential of Tmod in developing selective therapies for solid tumors.
  • To discuss the integration of Tmod with patient genomic selection for enhanced efficacy.

Main Methods:

  • Review of existing literature on NOT-gated immune cell integrators.
  • Focus on the Tmod system's mechanism of action.
  • Discussion of patient selection strategies based on tumor genomic lesions (loss of heterozygosity).

Main Results:

  • The Tmod system integrates activating and inhibitory receptor signals for precise immune responses.
  • This NOT-gated approach aims to improve selectivity in cancer treatment.
  • Quantitative preclinical data support the advancement of Tmod-based agents toward clinical application.

Conclusions:

  • The Tmod system represents a promising strategy for developing selective immunotherapies.
  • Combining Tmod with genomic patient selection offers a unique therapeutic opportunity for solid tumors.
  • Further clinical development is supported by robust preclinical evidence.